HLS Therapeutics Inc. (HLS.TO) TSX
Currency In CAD
- General
- Statistics
- Historical Data
- Profile
- Financials
HLS Therapeutics Inc.
Address
10 Carlson Court
Etobicoke, ON M9W 6L2
Canada
Phone
647-495-9000
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
92
First IPO Date
March 14, 2018
Key Executives
| Name | Title | Pay | Year Born |
| Craig Stuart Millian | Chief Executive Officer & Director | 1.36M | 1968 |
| Jason A. Gross | Vice President of Scientific Affairs | 416,645 | 1965 |
| Ryan C. Lennox | Senior Vice President of Legal, HR & Compliance and Corporate Secretary | 548,263 | 1981 |
| John Hanna | Chief Financial Officer & Non-Independent Director | 673,498 | 1965 |
| Brian T. Walsh | Chief Commercial Officer | 705,151 | N/A |
| David Spence | Vice President & Corporate Controller | 0 | 1968 |
| Dave Mason | Investor Relations Officer | 0 | N/A |
Description
HLS Therapeutics Inc. operates as a specialized pharmaceutical firm, concentrating on the acquisition and commercialization of medicinal products, primarily within the niche central nervous system (CNS) and cardiovascular (CV) sectors. Its reach extends across Canada, the United States, and international markets. The company's core product lineup includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsule formulation; and PERSERIS, an injectable risperidone product for treating schizophrenia. Additionally, HLS offers MyCare psychiatry laboratory assays and MyCare Insite tests for point-of-care therapeutic drug-level monitoring. Furthermore, the company possesses U.S. marketing privileges for Absorica, a commercial-stage dermatology solution, and Canadian rights for Trinomia, a cardiovascular therapeutic. It also manages a portfolio of royalty interests from four distinct healthcare products. Founded in 2018, HLS Therapeutics Inc. is based in Etobicoke, Canada.
